WO1999056725A1 - Compositions pharmaceutiques gelifiables - Google Patents

Compositions pharmaceutiques gelifiables Download PDF

Info

Publication number
WO1999056725A1
WO1999056725A1 PCT/EP1999/002551 EP9902551W WO9956725A1 WO 1999056725 A1 WO1999056725 A1 WO 1999056725A1 EP 9902551 W EP9902551 W EP 9902551W WO 9956725 A1 WO9956725 A1 WO 9956725A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
phospholipid
compositions
weight
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/002551
Other languages
English (en)
French (fr)
Inventor
Domenico Fanara
Henri Vranckx
Michel Deleers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP99923418A priority Critical patent/EP1073415B1/fr
Priority to IL13911399A priority patent/IL139113A0/xx
Priority to BR9910066-5A priority patent/BR9910066A/pt
Priority to NZ507707A priority patent/NZ507707A/en
Priority to US09/674,159 priority patent/US6464987B1/en
Priority to HK01103389.2A priority patent/HK1033263B/xx
Priority to AT99923418T priority patent/ATE307569T1/de
Priority to EA200001125A priority patent/EA002530B1/ru
Priority to CA002330500A priority patent/CA2330500C/fr
Priority to AU40308/99A priority patent/AU738455B2/en
Priority to DE69927963T priority patent/DE69927963T2/de
Priority to JP2000546752A priority patent/JP2002513748A/ja
Application filed by UCB SA filed Critical UCB SA
Priority to SI9930866T priority patent/SI1073415T1/sl
Priority to HU0101580A priority patent/HU226556B1/hu
Publication of WO1999056725A1 publication Critical patent/WO1999056725A1/fr
Priority to IS5669A priority patent/IS2354B/is
Priority to NO20005431A priority patent/NO20005431L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Definitions

  • the present invention relates to pharmaceutical compositions allowing the sustained release of at least one active substance, to processes for the preparation of these compositions, as well as to their use for the administration of medicaments by the subcutaneous route and / or intramuscular.
  • TRH thyrotropin releasing hormone a tripeptide
  • Another means of prolonging the release of an active principle consists in its incorporation in an implant.
  • These implants can be prepared from biodegradable polymers or not.
  • the drawback of this form is linked to its mode of subcutaneous introduction by incision or using a trocar.
  • the implant must be removed by incision after diffusion of all of the active ingredient out of the polymer matrix.
  • hormones such as LHRH (luteinizing hormone releasing hormone) and its synthetic analogues.
  • goserelin administered to humans in the form of implants of PLA-GA allows a very significant and lasting decrease in the level of testosterone in the blood (Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PF, Smith JA, Caplan RJ and Kennealey GT, Urolog, 46, 220 (1995)).
  • micro or nanoparticles can also be used: micro or nanoparticles.
  • biodegradable polymers are used. Compared to implants, these particles can be injected using a conventional syringe but have the disadvantage that they cannot be removed from the body. In case of problem. A very significant and lasting decrease in testosterone levels has also been observed in humans after administration of microparticles of PLA-GA containing nafarelin.
  • compositions obtained by an extremely simple preparation process and which allow a prolonged release of an active principle. These compositions have the property of instantly gelling in the presence of an aqueous phase. They can therefore be judiciously used to obtain, by the subcutaneous and intramuscular routes, a sustained and programmed release of drugs. On contact with the mucous membranes, a gel will form under the skin or in the muscle and the medicine may diffuse and be released from the gel. Lipid compositions which undergo a phase transformation on contact with water have already been presented in the literature.
  • European patent application 550960 describes compositions for topical application, intended to prevent sweating, comprising a sweating-preventing agent, which comprises at least one amphiphilic substance, this sweating-preventing agent being capable of forming a liquid crystalline phase insoluble in with a periodicity greater than 1.
  • Example 14 illustrates a composition capable of forming a reverse hexagonal crystalline phase in contact with perspiration, composed of 34 to 50% of oleic acid and of 50 to 66% lecithin (phosphatidylcholine).
  • International patent application WO 94/10978 describes emulsifying compositions intended to replace the synthetic emulsifiers commonly used in the food, cosmetic, grooming or pharmaceutical industry.
  • compositions comprise at least one membrane lipid (phospholipid), at least one natural amphiphile which is not a primary emulsifier (fatty acid or fatty alcohol C12 to C22, or combination of a fatty acid and a fatty alcohol), and, optionally, a hydrophilic medium (aliphatic alcohol such as propylene glycol).
  • phospholipid phospholipid
  • natural amphiphile fatty acid or fatty alcohol C12 to C22, or combination of a fatty acid and a fatty alcohol
  • hydrophilic medium aliphatic alcohol such as propylene glycol
  • Example 4 describes a composition consisting of 15% by weight of hydrogenated soy lecithin (phospholipid), 15% by weight of fatty acid, 45% by weight of fatty alcohol and 25% by weight of alcohol (10% ethanol and 15% glycerol).
  • This composition is in the form of a wax (soft waxy mass).
  • the literature also mentions fluid pharmaceutical compositions intended for the treatment of paradontitis, being in the form of more or less viscous suspensions or emulsions which are administered in the periodontal pocket, generally using syringes.
  • biodegradable lipid compositions in the form of L2 crystalline phases, allowing the controlled release of active substances and comprising, in addition to the active substance, at least one diacyl glycerol of unsaturated fatty acid having 16 with 22 carbon atoms or saturated fatty acid atoms having from 14 to 22 carbon atoms, and at least one phospholipid chosen from glycerophosphatides and sphingophosphatides, and, optionally, at least one polar liquid chosen from water, glycerol, ethylene glycol and propylene glycol.
  • compositions have the particularity of transforming in contact with water into cubic liquid crystalline phases, which makes it possible to "mold" the active substance in the site where it is desired that the action takes place.
  • This document mentions, among other applications, the possibility of using such compositions for the treatment of periodontitis.
  • the effectiveness of such compositions in the treatment of periodontitis is not illustrated in this document.
  • European patent 429224 describes compositions in the form of gels containing from 1 to 99% by weight of monoolein and from 1 to 90% by weight of active substance, which are placed in the periodontal cavity. In the presence of surrounding water, these compositions become more viscous and keep the active substance close to its site of action. The active substance is released slowly in a controlled manner.
  • US Patent 5,230,895 describes the use of compositions in the form of solutions or pastes capable of transforming into a gel when they have been placed in the periodontal pocket. These compositions are biodegradable and allow the controlled release of the active substance, in the site of action.
  • compositions illustrated in this document contain at least 70% of Myverol TM 18-92 which is a composition of sunflower monoglycerides having a monoglyceride content of at least 90%.
  • compositions allowing the administration by controlled release of an active substance in a periodontal pocket, comprising at least one monoglyceride and at least one vegetable oil in proportions sufficient to form a liquid crystalline phase in contact with the water present in the periodontal pocket.
  • These compositions are solid at room temperature, but have a melting point below body temperature.
  • the present invention relates to fluid pharmaceutical compositions allowing the controlled release of at least one active substance comprising a) a therapeutically effective amount of at least one active substance, b) from 3 to 55% by weight of phospholipid, c) from 16 at 72% by weight of pharmaceutically acceptable solvent, and d) from 4 to 52% by weight of fatty acid, these compositions having the property of instantly gelling in the presence of an aqueous phase.
  • the invention relates to processes for the preparation of these compositions.
  • antibiotics in particular antibiotics active against anaerobic bacteria such as doxycycline or minocycline and their pharmaceutically acceptable salts, anti-infectious agents, such as metronidazole, chlorhexidine, benzalkonium chloride , p-chloro-m-cresol, 1,2-dichlorobenzyl alcohol, hexamidine or chlorofen and their pharmaceutically acceptable salts, local anesthetics such as lidocaine, procaine, tetracaine, articaine, bupivacaine, mepivacaine or prilocaine and their pharmaceutically acceptable salts, steroidal anti-inflammatory drugs or others, such as hydrocortisone, cortisone, prednisone, prednisolone, methylprednisolone, triamcinolone, betamethasone or dexamethasone and pharmaceutically acceptable as well as aceclofenac, diclofenac, ibuprof
  • compositions according to the present invention contain from 3 to 55% of phospholipid.
  • the phospholipids which can be used according to the present invention are phosphoric esters of polyols and of fatty acids. They can come from a wide variety of sources, both natural and synthetically.
  • the phospholipids can be hydrogenated or non-hydrogenated. Examples that may be mentioned are phosphatidylcholine, hydrogenated phosphatidylcholine, phosphatidylglycerol salts, dicaproylphosphatidylcholine or salts of distearoylphosphatidylglycerol. These phospholipids can also be used as a mixture.
  • the phospholipid present in the compositions according to the present invention is phosphatidylcholine.
  • compositions according to the present invention can also contain up to 15% by weight of water.
  • amount of water present in the compositions according to the invention is chosen so that the composition has the desired consistency for the intended application.
  • phospholipids in the form of commercial mixtures are suitable for the compositions according to the present invention.
  • Phosal 50 PG TM 55.8% phosphatidylcholine, 1.9% soy fatty acids, 2.9% sunflower monoglycerides, 1.9% ethanol, 37 , 3% propylene glycol, 0.2% ascorbyl palmitate
  • Phosal 53 MCT TM 60.8% phosphatidylcholine, 2% oleic acid, 3% sunflower monoglycerides, 5% ethanol, 29% triglycerides, 0.2% ascorbyl palmitate
  • NATTERMANN PHOSPHOLIPID GmbH available from NATTERMANN PHOSPHOLIPID GmbH.
  • compositions according to the present invention can also contain the following optional components: up to 5% by weight of monoglyceride or diglyceride or of a mixture of mono- and diglyceride and / or up to 15% by weight of triglycerides.
  • compositions according to the present invention may also contain one or more preserving agents (such as ethanol), one or more antioxidant agents (such as ascorbyl palmitate) or one or more complexing agents (such as EDTA ( ethylenediamine tetraacetate)).
  • preserving agents such as ethanol
  • antioxidant agents such as ascorbyl palmitate
  • complexing agents such as EDTA ( ethylenediamine tetraacetate)
  • compositions according to the present invention allow the controlled release of at least one active substance.
  • controlled release is meant a release profile of the active substance desirable for the treatment envisaged.
  • the release of the active substance can therefore be more or less retained or slowed down depending on the active substance used and the desired therapeutic effect.
  • control of the release of the active substance can be easily obtained by simple variations in the proportions of the components of the compositions according to the present invention. They therefore lend themselves very well to various therapeutic applications in which the controlled release of an active substance is sought in a very specific biological site.
  • compositions according to the present invention are fluid pharmaceutical compositions in the form of emulsions, suspensions or oily preparations. They have the property of instantly gelling in the presence of an aqueous phase. In fact, when the compositions according to the present invention are placed in the presence of an excess of aqueous phase, they pass from a fluid state to a state of gel immiscible with the surrounding aqueous phase.
  • the present invention relates to methods of preparing the compositions according to the present invention.
  • the compositions according to the present invention are obtained by a process comprising the following successive stages: i) the phospholipid (s) are dissolved in the pharmaceutically acceptable solvent (s); ii) the fatty acid (s) are added to the phospholipid solution with stirring; iii) the active substance or substances are incorporated into the mixture obtained at the end of stage ii), and iv) water is optionally added to the composition obtained in stage iii).
  • the active substance is water-soluble, it is dissolved in a minimum quantity of water before incorporation in step iii).
  • step iii) When the substance active is not soluble in water, it is incorporated in step iii) in the mixture of phospholipid, pharmaceutically acceptable solvent and fatty acid. In the case of a substance which is both water-insoluble and little or no liposoluble, it is also incorporated in step iii), optionally in micronized form.
  • step iiii When the substance active is not soluble in water, it is incorporated in step iii) in the mixture of phospholipid, pharmaceutically acceptable solvent and fatty acid. In the case of a substance which is both water-insoluble and little or no liposoluble, it is also incorporated in step iii), optionally in micronized form.
  • the examples which follow illustrate the present invention without however limiting it. In these examples, all parts are expressed by weight.
  • the following commercial products were obtained from NATTERMANN PHOSPHOLIPID GmbH and have the following compositions (percentages by weight): - Phospholipon 90 TM: phosphatid
  • - Phosal 50 PG TM 55.8% phosphatidylcholine, 1.9% soy fatty acids, 2.9% sunflower monoglycerides, 1.9% ethanol, 37.3% propylene glycol, 0 , 2% ascorbyl palimitate;
  • - Phospholipon G-Na TM sodium salt of soybean 3 (3-sn-phosphatidyl) glycerol
  • - Phospholipon CC TM 1,2-dicaproyl-sn-glycero (3) phosphocholine
  • Phospholipon SG-Na TM sodium salt of 1,2-distearoyl-sn-glycero (3) phospholglycerol;
  • Example 2 The preparations Zj to Z5 prepared in Example 1 were subjected to a release test carried out according to the standards of the 23 rd edition of the US pharmacopoeia (USP 23), using apparatus No. 1 at a temperature of 37 ° C., the blades rotating at 50 rpm.
  • composition O Phospholipon 90 (30 parts by weight) is dissolved hot in polyethylene glycol 400 (45 parts by weight). After cooling, the oleic acid is added with stirring. On contact with an aqueous solution, the preparation instantly gels.
  • compositions P 40.9 parts of NAT 8449 TM are mixed with stirring,
  • compositions according to the present invention can contain different types of phospholipids.
  • the phospholipids used are the sodium salt of soybean 3- (3-sn-phosphatidyl) glycerol (Phospholipon G-Na TM), 1,2-dicaproyl-sn-glycero (3) phosphocholine (Phospholipon CC TM), the salt sodium 1,2-distearoyl-sn-glycero (3) phosphoglycerol (Phospholipon SG-Na TM) and hydrogenated soybean (3-sn-phosphatidyl) choline (Phospholipon 90H TM)
  • compositions S presented in Table 11 are obtained by mixing the various components with stirring. These four compositions instantly gel in the presence of an aqueous phase.
  • Example 7 Measurement of the release rate as a function of the excipients.
  • the release test is carried out as follows. Equal quantities of the preparations T j to T ⁇ and the control solution are placed in a well dug in the center of a layer of constant thickness of trypticase soy agar poured into a Petri dish. The rate of diffusion of the dye is determined by measuring the diameter of the dye stain as a function of time. The results obtained for the control solution and the Ti to T ⁇ solutions are included in the
  • compositions U listed in Table 14 were prepared.
  • Example 7.1 A release test as described in Example 7.1 is carried out on the compositions U1 to U4; for comparison, a release test is simultaneously carried out with the T7 solution and with a 10% solution of Sicomet-FDC blue 1 (control). The results of this test are presented in Table 15.
  • Example 8 In vivo tests. Subcutaneous and intramuscular injection of a calcitonin preparation. Calcitonin causes a decrease in the serum calcium level in direct relation to its activity. During these tests, the evolution over time of the serum calcium level in the rat was monitored after subcutaneous or intramuscular injection of preparations according to the invention containing 20 ⁇ l of salmon calcitonin.
  • compositions comprising salmon calcitonin used in these tests are listed in Table 16.
  • each rat receives subcutaneously in the abdominal region 200 ⁇ l of the preparation X ⁇ , ie 20 ⁇ l of calcitonin;
  • each rat receives subcutaneously in the abdominal region 200 ⁇ l of preparation X2, ie 20 ⁇ l of calcitonin;
  • each rat receives intramuscularly into the thigh muscle 200 ⁇ l of preparation X2, ie 20 ⁇ l of calcitonin; • series 6: each rat receives intramuscularly into the thigh muscle 200 ⁇ l of preparation X2, ie 20 ⁇ l of calcitonin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/EP1999/002551 1998-04-30 1999-04-16 Compositions pharmaceutiques gelifiables Ceased WO1999056725A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
IL13911399A IL139113A0 (en) 1998-04-30 1999-04-16 Pharmaceutical compositions capable of being gelled
BR9910066-5A BR9910066A (pt) 1998-04-30 1999-04-16 Composição farmacêutica fluida que permite a liberação controlada de pelo menos uma substância ativa, processo de fabricação de uma composição farmacêutica, e, utilização de uma composição
NZ507707A NZ507707A (en) 1998-04-30 1999-04-16 Gellable pharmaceutical compositions comprising active substance, phospholipid, solvent and fatty acid and their use for the controlled release of one or more active substances by subcutaneous and/or intramuscular injection
US09/674,159 US6464987B1 (en) 1998-04-30 1999-04-16 Pharmaceutical compositions capable of being gelled
HK01103389.2A HK1033263B (en) 1998-04-30 1999-04-16 Pharmaceutical compositions capable of being gelled
AT99923418T ATE307569T1 (de) 1998-04-30 1999-04-16 Gelierbare pharmazeutische zusammensetzungen
EA200001125A EA002530B1 (ru) 1998-04-30 1999-04-16 Гелеобразная фармацевтическая композиция, способ ее получения и применение
AU40308/99A AU738455B2 (en) 1998-04-30 1999-04-16 Gellable pharmaceutical compositions
CA002330500A CA2330500C (fr) 1998-04-30 1999-04-16 Compositions pharmaceutiques gelifiables
EP99923418A EP1073415B1 (fr) 1998-04-30 1999-04-16 Compositions pharmaceutiques gelifiables
JP2000546752A JP2002513748A (ja) 1998-04-30 1999-04-16 ゲル化性薬剤組成物
DE69927963T DE69927963T2 (de) 1998-04-30 1999-04-16 Gelierbare pharmazeutische zusammensetzungen
SI9930866T SI1073415T1 (sl) 1998-04-30 1999-04-16 Farmacevtske zmesi, ki zelirajo
HU0101580A HU226556B1 (en) 1998-04-30 1999-04-16 Pharmaceutical compositions capable of being gelled
IS5669A IS2354B (is) 1998-04-30 2000-10-17 Lyfjasamsetning sem mögulegt er að hleypa
NO20005431A NO20005431L (no) 1998-04-30 2000-10-27 Gelerbare farmasoytiske preparater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE9800329A BE1011899A6 (fr) 1998-04-30 1998-04-30 Compositions pharmaceutiques gelifiables utilisables.
BE98000329 1998-04-30

Publications (1)

Publication Number Publication Date
WO1999056725A1 true WO1999056725A1 (fr) 1999-11-11

Family

ID=3891230

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP1999/002551 Ceased WO1999056725A1 (fr) 1998-04-30 1999-04-16 Compositions pharmaceutiques gelifiables
PCT/EP1999/002552 Ceased WO1999056726A1 (fr) 1998-04-30 1999-04-16 Utilisation de compositions pharmaceutiques gelifiables en paradontologie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/002552 Ceased WO1999056726A1 (fr) 1998-04-30 1999-04-16 Utilisation de compositions pharmaceutiques gelifiables en paradontologie

Country Status (25)

Country Link
US (3) US6464987B1 (cg-RX-API-DMAC7.html)
EP (2) EP1073414B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002513748A (cg-RX-API-DMAC7.html)
KR (1) KR100567975B1 (cg-RX-API-DMAC7.html)
CN (1) CN1183901C (cg-RX-API-DMAC7.html)
AT (2) ATE219659T1 (cg-RX-API-DMAC7.html)
AU (2) AU3708599A (cg-RX-API-DMAC7.html)
BE (1) BE1011899A6 (cg-RX-API-DMAC7.html)
BG (1) BG64723B1 (cg-RX-API-DMAC7.html)
BR (1) BR9910066A (cg-RX-API-DMAC7.html)
CA (1) CA2330500C (cg-RX-API-DMAC7.html)
DE (2) DE69927963T2 (cg-RX-API-DMAC7.html)
DK (1) DK1073415T3 (cg-RX-API-DMAC7.html)
EA (1) EA002530B1 (cg-RX-API-DMAC7.html)
ES (2) ES2249891T3 (cg-RX-API-DMAC7.html)
HU (1) HU226556B1 (cg-RX-API-DMAC7.html)
ID (1) ID26221A (cg-RX-API-DMAC7.html)
IL (1) IL139113A0 (cg-RX-API-DMAC7.html)
IS (1) IS2354B (cg-RX-API-DMAC7.html)
NO (1) NO20005431L (cg-RX-API-DMAC7.html)
NZ (1) NZ507707A (cg-RX-API-DMAC7.html)
RS (1) RS50025B (cg-RX-API-DMAC7.html)
TR (1) TR200003158T2 (cg-RX-API-DMAC7.html)
WO (2) WO1999056725A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200005915B (cg-RX-API-DMAC7.html)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002041850A1 (de) 2000-11-22 2002-05-30 Beiersdorf Ag Haarpflegeprodukte mit einem gehalt an dispersen flüssigkristallen, welche kubische phasen darstellen
WO2003075885A1 (fr) 2002-03-12 2003-09-18 Ethypharm Composition a proprietes gelifiantes destinee a la delivrance prolongee de substances bio-actives
FR2837099A1 (fr) * 2002-03-12 2003-09-19 Ethypharm Sa Composition a proprietes gelifiantes destinee a la delivrance prolongee de substances bio-actives
JP2005506992A (ja) * 2001-10-19 2005-03-10 アイデックス ラボラトリーズ インコーポレイテッド 薬理学的に活性な化合物の制御送達のための注射用組成物
WO2005046642A1 (en) * 2003-11-07 2005-05-26 Camurus Ab Compositions of lipids and cationic peptides
JP2006523723A (ja) * 2003-04-18 2006-10-19 アイデックス ラボラトリーズ,インコーポレイティド 医薬的に活性な化合物を調節して導入する方法
US20060275353A1 (en) * 2002-05-31 2006-12-07 Nicholas V. Perricone Stable topical drug delivery compositions
US8435942B2 (en) * 2002-05-31 2013-05-07 Transdermal Biotechnology, Inc. Methods for formulating stabilized insulin compositions
US8668937B2 (en) 2011-03-17 2014-03-11 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US8815944B2 (en) 2008-01-31 2014-08-26 Ethypharm Pharmaceutical composition with gelling properties containing a tyrosine derivative
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9585931B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9597400B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9597401B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US10034914B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US10226511B2 (en) 2013-03-13 2019-03-12 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
CN1221249C (zh) 1998-08-19 2005-10-05 斯凯伊药品加拿大公司 普鲁泊福的可注射水分散体
US11026768B2 (en) 1998-10-08 2021-06-08 Align Technology, Inc. Dental appliance reinforcement
DE10024413A1 (de) * 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
US20050031650A1 (en) * 2002-08-26 2005-02-10 Ethypharm Composition with gelling properties for the sustained delivery of bioactive substances
DE10255195A1 (de) * 2002-11-27 2004-06-09 Lipoid Gmbh Micellare wasserlösliche Konzentrate
US20070232695A1 (en) * 2004-01-28 2007-10-04 Collegium Pharmaceutical, Inc. Gelled Periodontal Anesthetic Preparation
US9492245B2 (en) 2004-02-27 2016-11-15 Align Technology, Inc. Method and system for providing dynamic orthodontic assessment and treatment profiles
RU2288699C2 (ru) * 2004-03-23 2006-12-10 Дж. Б. Кемикалс Энд Фармасьютикалс Лимитед Гелевая композиция для лечения стоматологических заболеваний и способ ее получения
PL1768650T3 (pl) 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
US7858115B2 (en) * 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
JP5144267B2 (ja) * 2004-10-28 2013-02-13 アイデックス ラボラトリーズ,インコーポレイティド 医薬活性化合物を制御して搬送するための組成物
US20060115782A1 (en) * 2004-11-30 2006-06-01 Chunhua Li Systems and methods for coating a dental appliance
US20060115785A1 (en) 2004-11-30 2006-06-01 Chunhua Li Systems and methods for intra-oral drug delivery
US20060127437A1 (en) * 2004-12-13 2006-06-15 Misty Anderson Kennedy Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
EP1843746B1 (en) * 2005-01-14 2011-03-16 Camurus Ab Somatostatin analogue formulations
PL1845942T3 (pl) * 2005-01-14 2014-07-31 Camurus Ab Preparaty analogu GnRH
KR100983746B1 (ko) * 2005-01-14 2010-09-24 카무러스 에이비 소마토스타틴 유사 제형
US9649382B2 (en) * 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
PL1848403T3 (pl) * 2005-01-14 2010-09-30 Camurus Ab Preparaty bioadhezyjne o działaniu miejscowym
AU2005325510B2 (en) * 2005-01-21 2009-07-02 Camurus Ab Pharmaceutical lipid compositions
US8097239B2 (en) * 2005-06-06 2012-01-17 Camurus Ab Controlled-release formulations
PL1888031T3 (pl) 2005-06-06 2013-04-30 Camurus Ab Preparaty analogu glp-1
SE531318C2 (sv) * 2007-02-22 2009-02-24 Tigran Technologies Ab Publ Injicerbar suspension innefattande titan-,titanlegerings- eller titanoxidpartiklar av mikrostruktur
US7878805B2 (en) 2007-05-25 2011-02-01 Align Technology, Inc. Tabbed dental appliance
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
ES2582635T3 (es) * 2007-09-12 2016-09-14 Galderma Research & Development Utilización de excipientes como conservantes y composiciones farmacéuticas que los contienen
US8738394B2 (en) 2007-11-08 2014-05-27 Eric E. Kuo Clinical data file
US8108189B2 (en) 2008-03-25 2012-01-31 Align Technologies, Inc. Reconstruction of non-visible part of tooth
US9492243B2 (en) 2008-05-23 2016-11-15 Align Technology, Inc. Dental implant positioning
US8092215B2 (en) 2008-05-23 2012-01-10 Align Technology, Inc. Smile designer
US8172569B2 (en) 2008-06-12 2012-05-08 Align Technology, Inc. Dental appliance
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
WO2010033726A2 (en) 2008-09-17 2010-03-25 The Brigham And Women's Hospital, Inc. Drug delivery composition comprising a self-assembled gelator
US8152518B2 (en) 2008-10-08 2012-04-10 Align Technology, Inc. Dental positioning appliance having metallic portion
US8292617B2 (en) 2009-03-19 2012-10-23 Align Technology, Inc. Dental wire attachment
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI540132B (zh) * 2009-06-08 2016-07-01 亞培公司 Bcl-2族群抑制劑之口服醫藥劑型
PT2387391T (pt) * 2009-07-24 2017-04-20 Mika Pharma Ges Für Die Entw Und Vermarktung Pharmazeutischer Produkte Mbh Processo para o desenvolvimento de uma composição líquida a ser aplicada na forma de espuma sobre a pele e composição de aplicação tópica
US8765031B2 (en) 2009-08-13 2014-07-01 Align Technology, Inc. Method of forming a dental appliance
US8927009B2 (en) * 2009-12-22 2015-01-06 Abbvie Inc. ABT-263 capsule
SG183565A1 (en) * 2010-03-02 2012-09-27 Imagenetix Inc Compositions comprising myristic acid and uses thereof
US9211166B2 (en) 2010-04-30 2015-12-15 Align Technology, Inc. Individualized orthodontic treatment index
US9241774B2 (en) 2010-04-30 2016-01-26 Align Technology, Inc. Patterned dental positioning appliance
WO2012040623A2 (en) 2010-09-24 2012-03-29 The Brigham And Women's Hospital, Inc. Nanostructured gels capable of controlled release of encapsulated agents
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
EP2699267A4 (en) * 2011-04-18 2014-11-12 Lipidor Ab LIQUID CARRIER FOR THE ORAL DELIVERY OF A PHARMACOLOGICAL ACTIVE SUBSTANCE
US9403238B2 (en) 2011-09-21 2016-08-02 Align Technology, Inc. Laser cutting
US8716363B2 (en) * 2011-09-28 2014-05-06 Globus Medical, Inc. Biodegradable putty compositions and implant devices, methods, and kits relating to the same
US9555118B2 (en) * 2011-12-05 2017-01-31 Camrus Ab Robust controlled-release peptide formulations
BR112014014130A2 (pt) * 2011-12-21 2017-06-13 Hills Pet Nutrition Inc tratamento ou redução de condições dentárias com ésteres de ascorbilo
US9375300B2 (en) 2012-02-02 2016-06-28 Align Technology, Inc. Identifying forces on a tooth
US9220580B2 (en) 2012-03-01 2015-12-29 Align Technology, Inc. Determining a dental treatment difficulty
CN104427977B (zh) * 2012-05-10 2018-02-02 佩因拉佛姆有限公司 局部麻醉剂的储库制剂及其制备方法
US9414897B2 (en) 2012-05-22 2016-08-16 Align Technology, Inc. Adjustment of tooth position in a virtual dental model
PE20150195A1 (es) 2012-05-25 2015-02-27 Camarus Ab Formulaciones de agonistas del receptor de somatostatina
ES2837803T3 (es) 2012-07-26 2021-07-01 Camurus Ab Formulaciones de opioides
AU2013294915C1 (en) 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
US10449016B2 (en) 2014-09-19 2019-10-22 Align Technology, Inc. Arch adjustment appliance
US9610141B2 (en) 2014-09-19 2017-04-04 Align Technology, Inc. Arch expanding appliance
US9744001B2 (en) 2014-11-13 2017-08-29 Align Technology, Inc. Dental appliance with cavity for an unerupted or erupting tooth
US10504386B2 (en) 2015-01-27 2019-12-10 Align Technology, Inc. Training method and system for oral-cavity-imaging-and-modeling equipment
US9610242B2 (en) * 2015-08-18 2017-04-04 Concept Labs, Inc. Water-gel emulsion compositions and methods
US9962339B2 (en) 2015-10-08 2018-05-08 The Brigham And Women's Hospital, Inc. Stabilized assembled nanostructures for delivery of encapsulated agents
US11931222B2 (en) 2015-11-12 2024-03-19 Align Technology, Inc. Dental attachment formation structures
US11554000B2 (en) 2015-11-12 2023-01-17 Align Technology, Inc. Dental attachment formation structure
US11103330B2 (en) 2015-12-09 2021-08-31 Align Technology, Inc. Dental attachment placement structure
US11596502B2 (en) 2015-12-09 2023-03-07 Align Technology, Inc. Dental attachment placement structure
EP3452094B1 (en) 2016-05-06 2021-11-17 The Brigham and Women's Hospital, Inc. Binary self assembled gels for controlled delivery of encapsulated agents to cartilage
EP4670634A3 (en) 2016-06-17 2026-01-21 Align Technology, Inc. Intraoral appliances with sensing
EP3471653B1 (en) 2016-06-17 2021-12-22 Align Technology, Inc. Orthodontic appliance performance monitor
CN210727927U (zh) 2016-07-27 2020-06-12 阿莱恩技术有限公司 口内扫描系统
EP4295748A3 (en) 2016-11-04 2024-03-27 Align Technology, Inc. Methods and apparatuses for dental images
US11026831B2 (en) 2016-12-02 2021-06-08 Align Technology, Inc. Dental appliance features for speech enhancement
CA3043049A1 (en) 2016-12-02 2018-06-07 Align Technology, Inc. Methods and apparatuses for customizing rapid palatal expanders using digital models
US11376101B2 (en) 2016-12-02 2022-07-05 Align Technology, Inc. Force control, stop mechanism, regulating structure of removable arch adjustment appliance
ES2845198T3 (es) 2016-12-02 2021-07-26 Align Technology Inc Expansor palatino
US10548700B2 (en) 2016-12-16 2020-02-04 Align Technology, Inc. Dental appliance etch template
WO2018144991A1 (en) 2017-02-03 2018-08-09 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
US10779718B2 (en) 2017-02-13 2020-09-22 Align Technology, Inc. Cheek retractor and mobile device holder
US12090020B2 (en) 2017-03-27 2024-09-17 Align Technology, Inc. Apparatuses and methods assisting in dental therapies
US10613515B2 (en) 2017-03-31 2020-04-07 Align Technology, Inc. Orthodontic appliances including at least partially un-erupted teeth and method of forming them
CA3061480A1 (en) 2017-05-08 2018-11-15 Alivio Therapeutics, Inc. Formulation of nanostructured gels for increased agent loading and adhesion
US11045283B2 (en) 2017-06-09 2021-06-29 Align Technology, Inc. Palatal expander with skeletal anchorage devices
WO2018232299A1 (en) 2017-06-16 2018-12-20 Align Technology, Inc. Automatic detection of tooth type and eruption status
WO2019005808A1 (en) 2017-06-26 2019-01-03 Align Technology, Inc. BIOCAPTOR PERFORMANCE INDICATOR FOR INTRABUCCAL DEVICES
US10885521B2 (en) 2017-07-17 2021-01-05 Align Technology, Inc. Method and apparatuses for interactive ordering of dental aligners
CN114903623B (zh) 2017-07-21 2026-06-19 阿莱恩技术有限公司 颚轮廓锚固
CN110996836B (zh) 2017-07-27 2023-04-11 阿莱恩技术有限公司 用于通过光学相干断层扫描术来处理正畸矫正器的系统和方法
US11633268B2 (en) 2017-07-27 2023-04-25 Align Technology, Inc. Tooth shading, transparency and glazing
US12274597B2 (en) * 2017-08-11 2025-04-15 Align Technology, Inc. Dental attachment template tray systems
US11116605B2 (en) 2017-08-15 2021-09-14 Align Technology, Inc. Buccal corridor assessment and computation
WO2019036677A1 (en) 2017-08-17 2019-02-21 Align Technology, Inc. SURVEILLANCE OF CONFORMITY OF DENTAL DEVICE
US12171575B2 (en) 2017-10-04 2024-12-24 Align Technology, Inc. Intraoral systems and methods for sampling soft-tissue
US10813720B2 (en) 2017-10-05 2020-10-27 Align Technology, Inc. Interproximal reduction templates
CN114939001B (zh) 2017-10-27 2025-02-18 阿莱恩技术有限公司 替代咬合调整结构
WO2019089773A1 (en) 2017-10-31 2019-05-09 Align Technology, Inc. Dental appliance having selective occlusal loading and controlled intercuspation
CN119235481A (zh) 2017-11-01 2025-01-03 阿莱恩技术有限公司 自动治疗规划
WO2019100022A1 (en) 2017-11-17 2019-05-23 Align Technology, Inc. Orthodontic retainers
WO2019108978A1 (en) 2017-11-30 2019-06-06 Align Technology, Inc. Sensors for monitoring oral appliances
US11432908B2 (en) 2017-12-15 2022-09-06 Align Technology, Inc. Closed loop adaptive orthodontic treatment methods and apparatuses
US10980613B2 (en) 2017-12-29 2021-04-20 Align Technology, Inc. Augmented reality enhancements for dental practitioners
EP4792730A2 (en) 2018-01-26 2026-08-19 Align Technology, Inc. Intraoral scanning system
US11937991B2 (en) 2018-03-27 2024-03-26 Align Technology, Inc. Dental attachment placement structure
CN108498376B (zh) * 2018-04-02 2020-11-13 榛硕(武汉)智能科技有限公司 一种甲基硅油乳液及其制备方法
WO2019200008A1 (en) 2018-04-11 2019-10-17 Align Technology, Inc. Releasable palatal expanders
CN113825495A (zh) 2018-10-11 2021-12-21 阿利维奥治疗学股份有限公司 用于智能释放的不可注射水凝胶调配物
WO2020079706A1 (en) 2018-10-15 2020-04-23 Cipla Limited Pharmaceutical formulation
EP3848016A1 (en) * 2020-01-08 2021-07-14 3M Innovative Properties Company Oral care composition containing fatty acid components for treating caries
US11992483B2 (en) 2021-03-31 2024-05-28 Cali Biosciences Us, Llc Emulsions for local anesthetics
JP7092922B1 (ja) * 2021-06-11 2022-06-28 キユーピー株式会社 製剤
CN122295112A (zh) * 2023-11-22 2026-06-26 Mx生物株式会社 一种用于预防或治疗牙周疾病的组合物以及牙科用复合抗生素软膏组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0429224A1 (en) * 1989-11-17 1991-05-29 The Procter & Gamble Company Use of monoolein in the treatment of the periodontal pocket
EP0550960A1 (en) * 1991-11-12 1993-07-14 Unilever Plc Antiperspirant materials and compositions
WO1994010978A1 (en) * 1992-11-16 1994-05-26 Phares Pharmaceutical Holland B.V. Method for the preparation of creams
WO1995003787A1 (en) * 1993-07-28 1995-02-09 University Of Saskatchewan Biphasic multilamellar lipid vesicles
WO1997015285A1 (en) * 1995-10-27 1997-05-01 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5230899A (en) * 1985-08-07 1993-07-27 Smithkline Beecham Corporation Methods and compositions for making liposomes
US5230895A (en) * 1990-05-01 1993-07-27 Copley Pharmaceutical Inc. Sustained released delivery system for use in the periodontal pocket
US5567456A (en) * 1991-11-04 1996-10-22 Creative Products Inc. Of Rossville Food release compositions with organic fluidizing agents
JP3190441B2 (ja) * 1992-07-20 2001-07-23 エーザイ株式会社 塩酸アゼラスチンを含有する安定な製剤
DE19536246A1 (de) * 1994-09-30 1996-04-04 Juergen Dr Regenold Pharmazeutische Zusammensetzung
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0429224A1 (en) * 1989-11-17 1991-05-29 The Procter & Gamble Company Use of monoolein in the treatment of the periodontal pocket
EP0550960A1 (en) * 1991-11-12 1993-07-14 Unilever Plc Antiperspirant materials and compositions
WO1994010978A1 (en) * 1992-11-16 1994-05-26 Phares Pharmaceutical Holland B.V. Method for the preparation of creams
WO1995003787A1 (en) * 1993-07-28 1995-02-09 University Of Saskatchewan Biphasic multilamellar lipid vesicles
WO1997015285A1 (en) * 1995-10-27 1997-05-01 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system

Cited By (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002041850A1 (de) 2000-11-22 2002-05-30 Beiersdorf Ag Haarpflegeprodukte mit einem gehalt an dispersen flüssigkristallen, welche kubische phasen darstellen
JP2005506992A (ja) * 2001-10-19 2005-03-10 アイデックス ラボラトリーズ インコーポレイテッド 薬理学的に活性な化合物の制御送達のための注射用組成物
JP4850390B2 (ja) * 2001-10-19 2012-01-11 アイデックス ラボラトリーズ インコーポレイテッド 薬理学的に活性な化合物の制御送達のための注射用組成物
AU2003227827B2 (en) * 2002-03-12 2008-09-25 Ethypharm Composition having gelling properties for the prolonged delivery of bioactive substances
FR2837099A1 (fr) * 2002-03-12 2003-09-19 Ethypharm Sa Composition a proprietes gelifiantes destinee a la delivrance prolongee de substances bio-actives
JP2005528352A (ja) * 2002-03-12 2005-09-22 エチファルム 生体活性物質の持続的放出に用いるためのゲル化特性を有する組成物
NO339426B1 (no) * 2002-03-12 2016-12-12 Ethypharm Sa Sammensetning som har gelerende egenskaper til forsinket levering av bioaktive stoffer
WO2003075885A1 (fr) 2002-03-12 2003-09-18 Ethypharm Composition a proprietes gelifiantes destinee a la delivrance prolongee de substances bio-actives
US20060275353A1 (en) * 2002-05-31 2006-12-07 Nicholas V. Perricone Stable topical drug delivery compositions
US20110123577A1 (en) * 2002-05-31 2011-05-26 Perricone Nicholas V Method Of Delivering Stable Topical Drug Compositions
US8435942B2 (en) * 2002-05-31 2013-05-07 Transdermal Biotechnology, Inc. Methods for formulating stabilized insulin compositions
US9050248B2 (en) 2002-05-31 2015-06-09 Transdermal Biotechnology, Inc. Methods of delivering stable topical drug compositions
US9060925B2 (en) 2002-05-31 2015-06-23 Transdermal Biotechnology, Inc. Methods of delivering stable topical drug compositions
JP2006523723A (ja) * 2003-04-18 2006-10-19 アイデックス ラボラトリーズ,インコーポレイティド 医薬的に活性な化合物を調節して導入する方法
US8865021B2 (en) 2003-11-07 2014-10-21 Camurus Ab Compositions of lipids and cationic peptides
WO2005046642A1 (en) * 2003-11-07 2005-05-26 Camurus Ab Compositions of lipids and cationic peptides
US8815944B2 (en) 2008-01-31 2014-08-26 Ethypharm Pharmaceutical composition with gelling properties containing a tyrosine derivative
US9937202B2 (en) 2011-03-17 2018-04-10 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US9517179B2 (en) 2011-03-17 2016-12-13 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US8668937B2 (en) 2011-03-17 2014-03-11 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US9480709B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US9480706B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US9198853B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9198931B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US9198854B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US9198970B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US9198933B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US9198930B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US9198932B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9205043B2 (en) 2012-09-19 2015-12-08 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US10034898B2 (en) 2012-09-19 2018-07-31 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9295638B2 (en) 2012-09-19 2016-03-29 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US10034897B2 (en) 2012-09-19 2018-07-31 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US10034896B2 (en) 2012-09-19 2018-07-31 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US9968634B2 (en) 2012-09-19 2018-05-15 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9968635B2 (en) 2012-09-19 2018-05-15 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US9950004B2 (en) 2012-09-19 2018-04-24 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US9844565B2 (en) 2012-09-19 2017-12-19 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US9827266B2 (en) 2012-09-19 2017-11-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US9795632B2 (en) 2012-09-19 2017-10-24 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9480705B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US9480707B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9480711B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9480710B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US9480708B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US9585931B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9844506B2 (en) 2013-03-13 2017-12-19 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9439926B2 (en) 2013-03-13 2016-09-13 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9498535B2 (en) 2013-03-13 2016-11-22 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9585829B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9585817B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9597400B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9597401B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9636291B2 (en) 2013-03-13 2017-05-02 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9682102B2 (en) 2013-03-13 2017-06-20 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9687504B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9694083B2 (en) 2013-03-13 2017-07-04 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9694029B2 (en) 2013-03-13 2017-07-04 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9700626B2 (en) 2013-03-13 2017-07-11 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9717680B2 (en) 2013-03-13 2017-08-01 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9757467B2 (en) 2013-03-13 2017-09-12 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9827316B2 (en) 2013-03-13 2017-11-28 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9480642B2 (en) 2013-03-13 2016-11-01 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9872818B2 (en) 2013-03-13 2018-01-23 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9913793B2 (en) 2013-03-13 2018-03-13 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9931370B2 (en) 2013-03-13 2018-04-03 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9937221B2 (en) 2013-03-13 2018-04-10 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9943562B2 (en) 2013-03-13 2018-04-17 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9956290B2 (en) 2013-03-13 2018-05-01 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US10028994B2 (en) 2013-03-13 2018-07-24 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US10034944B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US10034914B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US10034828B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US10064955B2 (en) 2013-03-13 2018-09-04 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US10071117B2 (en) 2013-03-13 2018-09-11 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US10080768B2 (en) 2013-03-13 2018-09-25 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US10155048B2 (en) 2013-03-13 2018-12-18 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US10188603B2 (en) 2013-03-13 2019-01-29 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US10213457B2 (en) 2013-03-13 2019-02-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US10226511B2 (en) 2013-03-13 2019-03-12 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions

Also Published As

Publication number Publication date
CA2330500A1 (fr) 1999-11-11
KR100567975B1 (ko) 2006-04-07
CN1301147A (zh) 2001-06-27
EP1073414B1 (fr) 2002-06-26
HK1033263A1 (en) 2001-08-24
HUP0101580A3 (en) 2002-10-28
IS2354B (is) 2008-04-15
DE69901951D1 (de) 2002-08-01
US20030199477A1 (en) 2003-10-23
DE69927963T2 (de) 2006-06-29
EA200001125A1 (ru) 2001-04-23
JP2002513748A (ja) 2002-05-14
HUP0101580A2 (hu) 2002-03-28
KR20010043000A (ko) 2001-05-25
EP1073415A1 (fr) 2001-02-07
AU738455B2 (en) 2001-09-20
CA2330500C (fr) 2009-06-16
ES2249891T3 (es) 2006-04-01
DE69927963D1 (de) 2005-12-01
ID26221A (id) 2000-12-07
EP1073415B1 (fr) 2005-10-26
DK1073415T3 (da) 2006-03-06
US6464987B1 (en) 2002-10-15
AU4030899A (en) 1999-11-23
ATE307569T1 (de) 2005-11-15
YU66600A (sh) 2003-04-30
RS50025B (sr) 2008-11-28
HU226556B1 (en) 2009-03-30
IS5669A (is) 2000-10-17
ATE219659T1 (de) 2002-07-15
NO20005431D0 (no) 2000-10-27
EP1073414A1 (fr) 2001-02-07
AU3708599A (en) 1999-11-23
NZ507707A (en) 2002-05-31
BG64723B1 (bg) 2006-01-31
BE1011899A6 (fr) 2000-02-01
ES2178430T3 (es) 2002-12-16
EA002530B1 (ru) 2002-06-27
TR200003158T2 (tr) 2001-03-21
WO1999056726A1 (fr) 1999-11-11
JP2002513749A (ja) 2002-05-14
BR9910066A (pt) 2000-12-26
US6471970B1 (en) 2002-10-29
DE69901951T2 (de) 2002-11-28
IL139113A0 (en) 2001-11-25
CN1183901C (zh) 2005-01-12
US6818224B2 (en) 2004-11-16
BG104872A (bg) 2001-07-31
ZA200005915B (en) 2001-10-23
NO20005431L (no) 2000-12-19

Similar Documents

Publication Publication Date Title
EP1073415B1 (fr) Compositions pharmaceutiques gelifiables
CN1172674C (zh) 促进渗透和减少刺激的系统
CA2231342C (fr) Composition pharmaceutique pour administration par voie orale
FR2814074A1 (fr) Nouvelles compositions estro-progestatives topiques a effet systemique
FR2803516A1 (fr) Formulation injectable de fulvestrant
CA2711961A1 (fr) Compositions pharmaceutiques transcutanees contenant une hormone steroidienne
FR2753376A1 (fr) Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques
CA2443728C (fr) Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie
EP0359625B1 (fr) Dispositif auto-adhésif d'administration d'un principe actif par voie percutanée
WO2008007001A1 (fr) Formulation injectable à libération prolongée de principes actifs, procédé pour sa préparation
EP4294364A2 (fr) Composition emulsion et ses utilisations dans la prevention et/ou le traitement des dommages cutanes causes par les rayonnements
MXPA00010497A (en) Pharmaceutical compositions capable of being gelled
CZ20004010A3 (cs) Farmaceutické kompozice schopné vytvářet gel
HK1033263B (en) Pharmaceutical compositions capable of being gelled
EP2678024A1 (fr) Compositions pharmaceutiques administrables par voie cutanée et destinées au traitement local de la dermatite atopique canine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200000948

Country of ref document: VN

Ref document number: P-666/00

Country of ref document: YU

Ref document number: 99806266.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 139113

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 507707

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1999923418

Country of ref document: EP

Ref document number: 2000/05915

Country of ref document: ZA

Ref document number: 200005915

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020007011844

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1999EP 9902551

Country of ref document: KE

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999EP9902551

Country of ref document: KE

ENP Entry into the national phase

Ref document number: 2330500

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/010497

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV2000-4010

Country of ref document: CZ

Ref document number: 09674159

Country of ref document: US

Ref document number: 40308/99

Country of ref document: AU

Ref document number: 2000/03158

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 200001125

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1999923418

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-4010

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007011844

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 40308/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999923418

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1020007011844

Country of ref document: KR